Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Phase 2 Completed 48 enrolled Accelerated Community Oncology Research Network Celgene Corporation · collab Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.

Timeline

Start: 2007-01
Primary completion: 2011-02
Completion: 2011-02

Publications

Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol. 2013 Feb;128(2):221-8. doi: 10.1016/j.ygyno.2012.08.039. Epub 2012 Sep 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abraxane	Small molecule	100 mg/m2	Intravenous
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Summary

Timeline

Publications

Drugs

Indications